Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Interest & Investment Income (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Interest & Investment Income for 15 consecutive years, with $152000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest & Investment Income fell 70.54% year-over-year to $152000.0, compared with a TTM value of $958000.0 through Sep 2025, down 31.47%, and an annual FY2024 reading of $1.7 million, up 281.41% over the prior year.
  • Interest & Investment Income was $152000.0 for Q3 2025 at Fennec Pharmaceuticals, down from $171000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $570000.0 in Q2 2024 and bottomed at $9000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $180375.0, with a median of $133500.0 recorded in 2023.
  • The sharpest move saw Interest & Investment Income surged 1111.11% in 2023, then crashed 70.54% in 2025.
  • Year by year, Interest & Investment Income stood at $13000.0 in 2021, then soared by 1084.62% to $154000.0 in 2022, then dropped by 25.32% to $115000.0 in 2023, then skyrocketed by 246.96% to $399000.0 in 2024, then plummeted by 61.9% to $152000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for FENC at $152000.0 in Q3 2025, $171000.0 in Q2 2025, and $236000.0 in Q1 2025.